Navigation Links
Investigational Drug May Help Avert Blood Clots
Date:3/13/2009

Researchers say it works even when common blood thinners also are taken

FRIDAY, March 13 (HealthDay News) -- A drug derived from the magnolia tree appears to be safe and tolerable in preventing blood clots, according to a phase 2 study conducted by researchers at the Duke Clinical Research Institute.

The trial included 1,030 people, 45 years and older, who were scheduled to undergo either percutaneous coronary intervention (PCI) -- a procedure to clear clogged arteries and keep them open with stents -- or angiography and then PCI. People having PCI are usually prescribed drugs, such as aspirin or clopidogrel, to prevent potentially dangerous blood clots.

The study participants were randomly assigned to receive one of three doses (10, 20 or 40 milligrams) of the new drug, called SCH 530348, or a placebo. Aspirin and clopidogrel were not prescribed as part of the study but were allowed, and 95 percent of people in the study took both drugs, the researchers said.

They found that the new drug was generally tolerable at all dosing levels and did not increase bleeding, even when taken with aspirin and clopidogrel. Bleeding occurred in 2 percent of the 129 people who took 10 mg, in 3 percent of those who took 20 mg, in 4 percent of those who took 40 mg and in 3 percent of the placebo group.

Participants were also given different maintenance doses of the drug. Bleeding occurred in 2 percent of those who took 0.5 mg, in 4 percent who took 1 mg, in 3 percent who took 2.5 mg and in 2 percent of those who took the placebo.

The findings were released online and published in the March 14 print issue of The Lancet. The study was funded by Schering-Plough, and a number of the study's authors received consulting fees from the drug maker or own stock in the company.

The researchers said that SCH 530348 appears able to uncouple two important functions of thrombin in the formation of blood clots
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

1

GOOD

Page: 1 2

Related medicine news :

1. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
2. PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
3. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
4. Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
5. AUDIO from Medialink and Genzyme: Study in New England Journal of Medicine Shows Investigational Compound Reduced Relapses and Disability in Patients With MS
6. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
7. Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage
8. NEW DATA FOR PAZOPANIB - GSKS LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS
9. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
10. UAB study shows investigational drug may treat biliary cancers
11. Investigational anti-restenosis drug pimecrolimus disappoints
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Investigational Drug May Help Avert Blood Clots
(Date:5/21/2013)... roles two proteins, thrombospondin-1 and prosaposin, play in ... identified a five-amino acid fragment of prosaposin that ... prostate, breast and lung cancer. The findings suggest ... in a variety of cancers. , The ... Boston Children,s Hospital, Vivek Mittal, PhD, at Weill ...
(Date:5/21/2013)... the removal of the adenoids and tonsils, is performed ... as a treatment for children with obstructive sleep apnea. ... attention and executive functioning, behavior, sleep apnea symptoms, and ... now. A study led by Susan Redline, MD, ... Cardiovascular Medicine and Associate Clinic Director of the Division ...
(Date:5/21/2013)... Harbor, Florida (PRWEB) May 21, 2013 ... agency, announced today that they have redesigned their website ... a nude beach, pool, hot tubs, bars and dining. ... this nudist resort including sales and guest reviews, will ... island of Jamaica itself, including pages on culinary local ...
(Date:5/21/2013)... The American Diabetes Association ( http://goo.gl/YRSF1 ... United States of America are affected with peripheral neuropathy. ... risk of developing peripheral neuropathy which unfortunately makes it ... further goes on saying that the disease usually affects ... million new cases are diagnosed every year in the ...
(Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
Breaking Medicine News(10 mins):Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2
... Two Chinese soybean lines that grow without the primary ... have been isolated by scientists//. ,The two lines ... given away to breeders seeking to produce new varieties ... scientists at the University of Illinois at Urbana-Champaign and ...
... into action by mutations of the virus into a human flu ... what plan of action can we rely on to control the ... countries are teaming up next month to roll out a mock ... a pandemic. ,Australia and Singapore will be co-coordinating the ...
... of the out of hours health care system in England as ... ,The public accounts committee claimed that the new health care ... many key targets. ,In 2004 most GPs had opted ... PCTs took over in 90% of cases. ,The NAO ...
... plans for slow suffocation of millions of poultry, in ... ,According to Compassion in World Farming (CIWF) ... have been amended under emergency procedures whereby the Secretary ... a method of culling poultry in the event of ...
... a type 1 diabetic has been reported missing in West ... of medication// leaving her gravely ill, police have appealed for ... home in Uphall, at 2 pm on Monday. Stephanie went ... in Livingston. She is white, 5 ft 2in, of stocky ...
... University in Scotland found that women with high levels ... following in vitro fertilization. They found that the supplement ... after fertility treatment. ,However, the researchers said ... birth defects such as spina bifida, does not affect ...
Cached Medicine News:Health News:Promise for Soya Allergy Sufferers 2Health News:High Levels Of Folic Acid May Increase The Chances Of Twins After IVF 2
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... -- U.S. spending on specialty prescription drugs — those ... multiple sclerosis and rheumatoid arthritis — is projected to ... to a forecast released today by Express Scripts (NASDAQ: ... "As we see what,s on the horizon, ... so they can continue to offer an affordable pharmacy ...
(Date:5/21/2013)... , May 21, 2013  AcelRx Pharmaceuticals, ... specialty pharmaceutical company focused on the development ... treatment of acute and breakthrough pain, today ... placebo-controlled Phase 3 study of its investigational ... (NanoTab System), the primary efficacy endpoint was ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... REDWOOD CITY, Calif., May 6, 2011 AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today announced that Richard King, President and Chief Executive ... Research Conference at the San Francisco Ritz Carlton. The ...
... MIAMI, May 6, 2011 SaveRxCanada.com the premier Canadian pharmacy ... still purchase Canada drugs from a Canada pharmacy ... Canada drugs can be 85% less than the U.S. ... clientele since 2002. 2. Convenience – Many patients are ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference 2Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2
The Foundation PS knee offers a femoral option and tibial insert which provides a specially designed cam action that engages at 60 degrees of flexion to induce a smooth stable femoral roll-back motio...
... Natural Knee design includes several ... CSTi porous coating option for ... a unique bone preserving posterior ... groove to maximize range of ...
... Total Knee System provides anatomical replacement of ... while preserving the stabilizing Anterior and Posterior ... motion of the knee. All the components ... sizes and are equally proportioned and contoured ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Medicine Products: